Thrombotic microangiopathy: a case report and review of the literature.

Thrombotic microangiopathy most likely represents a spectrum of diseases consisting of multiple etiologies that has a final common pathway of multiorgan microvascular thrombosis. The variable responses to several different modes of therapy would suggest that more than one pathogenetic mechanism is involved. Untreated, it has been associated with very high morbidity and mortality rates. A poor understanding of the basic disease process has prevented specific treatment modalities, although early diagnosis and availability of dialysis and blood product transfusion services remain crucial. Several modes of therapy have been used to date, with plasma exchange being the most effective method studied and shown to improve survival. On the basis of current knowledge, this form of treatment should be instituted promptly in severe cases. Anecdotal reports of recovery with vincristine or IgG alone or with the use of IgG after the apparent failure of plasma therapy appear promising and deserve further investigation as initial therapeutic measures used in thrombotic microangiopathy. Although the majority of patients recover with normal renal function, those with severe thrombotic microangiopathy may heal through sclerosis with residual hypertension and chronic renal impairment requiring continual medical therapy.

[1]  W. Bell,et al.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. , 1991, The New England journal of medicine.

[2]  G. Remuzzi,et al.  HUS and TTP: Variable expression of a single entity , 1987 .

[3]  A. Y. Chiu,et al.  Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G. , 1984, The Journal of clinical investigation.

[4]  D. Deykin,et al.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. , 1982, The New England journal of medicine.

[5]  J. Byrnes,et al.  Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. , 1979, Blood.

[6]  H. Kwaan,et al.  The Nature of the Vascular Lesion in Thrombotic Thrombocytopenic Purpura. , 1968 .

[7]  G. Carlos,et al.  The hemolytic-uremic syndrome , 1964 .

[8]  B. Kagan,et al.  Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. , 1959, Annals of internal medicine.

[9]  R. Bukowski,et al.  The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. , 1987, Seminars in hematology.

[10]  Jordan J. Cohen,et al.  HUS and TTP: Variable expression of a single entity , 1987 .

[11]  G. Eknoyan,et al.  Renal involvement in patients with thrombotic thrombocytopenic purpura. , 1986, American journal of nephrology.

[12]  R. Livingston,et al.  Therapy of Thrombotic Thrombocytopenic Purpura: An Overview , 1981, Seminars in thrombosis and hemostasis.

[13]  J. Byrnes Thrombotic thrombocytopenic purpura. , 1980, Advances in internal medicine.

[14]  G. Remuzzi,et al.  Thrombotic thrombocytopenic purpura--a deficiency of plasma factors regulating platelet-vessel-wall interaction? , 1978, The New England journal of medicine.

[15]  E. Moschcowitz Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease , 1924 .